Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study
Carfilzomib administered as either KRd or Kd was effective and well tolerated, even in patients with multiple prior LOTs, confirming the safety and response rates observed from clinical trials and real-world studies.
Authors
- Si Yun Melinda Tan
- Ming‐Chung Wang (ORCID: https://orcid.org/0009-0005-2375-4571)
- Megan Braunlin (ORCID: https://orcid.org/0000-0002-1730-9691)
- Raymond Wong (ORCID: https://orcid.org/0000-0002-9011-4268)
- Ki-Hong Chang
- Rani Najdi
- Hang Quach (ORCID: https://orcid.org/0000-0002-4796-3352)
- Mihaela Talpes
- Kihyun Kım (ORCID: https://orcid.org/0000-0002-5878-8895)
- Jin Seok Kim (ORCID: https://orcid.org/0000-0001-8986-8436)
Institutions
- Amgen (United States) (US)
- Chinese University of Hong Kong (HK)
- Singapore General Hospital (SG)
- Samsung Medical Center (KR)
- St Vincent's Hospital Melbourne (AU)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Prince of Wales Hospital (CN)
- Yonsei University Health System (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1016/j.clml.2025.05.001
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen